Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study
Frontiers in Oncology · 10.06.2026 · 16
DOI: 10.3389/fonc.2026.1785622 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Oncology, online erschienen am 10.06.2026. Verfasst von Liying Tian und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Second Ward of the Department of Gastroenterology, Handan Central Hospital, Handan, China. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Drug-eluting bead (DEB) transarterial chemoembolization (TACE) possesses several advantages over conventional TACE (cTACE) such as higher intratumor drug concentration and lower systemic toxicity, which has been widely applied in hepatocellular carcinoma patients, but related information is insufficient in patients with colorectal cancer liver metastases (CRCLM). This study aimed to investigate the efficacy and safety of DEB-TACE versus cTACE in treating elderly CRCLM patients.
Methods
A total of 43 elderly patients with unresectable CRCLM were retrospectively analyzed in this cohort study, among which 20 cases received DEB-TACE and 23 cases received cTACE. Best treatment response, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were collected.
Results
Baseline characteristics were comparable between the DEB-TACE and cTACE groups, with no statistically significant differences observed. Complete response rate (10.0% versus 4.3%, P = 0.468), objective response rate (55.0% versus 30.4%, P = 0.103), and disease control rate (95.0% versus 82.6%, P = 0.206) showed higher tendencies in the DEB-TACE group compared with the cTACE group but did not reach statistical significance. PFS was longer in the DEB-TACE group compared with the cTACE group [median: 11.7 (95% CI: 7.5–15.9) versus 6.1 (95% CI: 5.1–7.1) months, P = 0.013], but OS only exhibited a prolonged tendency without statistical significance [21.6 (95% CI: 14.3–28.9) versus 16.3 (95% CI: 11.6–21.0) months, P = 0.076]. The incidence of AEs was not different between the DEB-TACE and cTACE groups, including fever, pain, nausea and vomiting, ALT elevation, AST elevation, anemia, leukopenia, and thrombocytopenia.
Conclusion
DEB-TACE can be an optional choice for the treatment of elderly CRCLM patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Second Ward of the Department of Gastroenterology, Handan Central Hospital, Handan, China.
- The Second Department of Vascular Intervention, Handan Central Hospital, Handan, China.
- Emergency Surgery, Beijing Children's Hospital Capital Medical University, Beijing, China.
- Cardiovascular Surgery, Hebei Medical University Third Hospital, Shijiazhuang, China.
- Child Care, Merice Cody Public School, Toronto, ON, Canada.
Zitieren
APA
Tian, L., Hu, B., Song, M., Li, Y., Yang, F., & Yang, J. (2026). Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1785622
Vancouver
Tian L, Hu B, Song M, Li Y, Yang F, Yang J. Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1785622
BibTeX
@article{Tian2026,
author = {Tian, Liying and Hu, Bao and Song, Meifang and Li, Yunpeng and Yang, Fan and Yang, Jiecheng},
title = {Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1785622}
}
EUVIMED